- The key vendors in the Global CKD Drugs Market 2015-2019 are Actavis plc, Amgen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Ltd. and Sanofi SA
London, 03 March 2015: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global CKD Drugs Market 2015-2019. Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market. The Global CKD Drugs market is expected to grow at a CAGR of 1.21 percent during the forecast period of 2014-2019.
The upsurge in prevalence of CKD across the globe has given an opportunity for the CKD drug manufacturers. The steady growth in the market is a result of a rise in diagnostic centers and advances in therapeutics.
“Major pharmaceutical companies in the nephrology therapeutic domain are investing heavily in R&D to develop new drugs for CKD,” says Faisal Ghaus, Vice President of TechNavio Research.
“For instance, in 2014 OPKO Health developed effective marketing strategies for new drugs to treat CKD. This is an important milestone for the company in Renal Division for development and launch of proprietary products.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
